Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in Paris, France. It specializes in medical treatments for neurology, immunology, oncology, rare diseases, diabetes, and cardiovascular ...

which the company plans to separate through the creation of a publicly-listed entity headquartered in Paris to be called Opella. Sanofi is conducting exclusive negotiations with CD&R, a U.S.-based ...

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...

(ATR) French multinational pharmaceutical company Sanofi has been designated a premium partner of the 2024 Olympic and Paralympic Games in Paris. Headquartered in the 2024 Games host city ...

Sanofi has launched a new initiative in its drive to integrate digital technologies throughout its business, setting up an accelerator based in Paris that will serve as the lynchpin of the effort.

coli is being jointly developed by Sanofi and Johnson and Johnson (NYSE:JNJ). No safety signals related to the vaccine candidate were identified, the Paris-based healthcare company said in a ...

If the need is covered elsewhere already then the channel is not going to be very successful," said Olba at last week's Doctors2.0 & You conference in Paris. "In Spain, Sanofi has taken a highly ...

The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for ...

N.Y. and PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for ...

Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: • €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor ...